Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silexion Therapeutics ( (SLXN) ) has issued an announcement.
On September 23, 2025, Silexion Therapeutics Corp. received confirmation from Nasdaq that it had restored compliance with the shareholders’ equity and minimum bid price requirements necessary for continued listing on the Nasdaq Capital Market. This follows a series of strategic financial moves, including a 1-for-15 reverse share split and financing transactions that increased the company’s shareholders’ equity. The company will be under a mandatory panel monitor until September 23, 2026, to ensure ongoing compliance.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp. operates within the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is listed on the Nasdaq Capital Market and is committed to maintaining compliance with Nasdaq’s listing requirements.
Average Trading Volume: 404,051
Technical Sentiment Signal: Sell
Current Market Cap: $8.19M
For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.